Flex Pharma, Inc. is a biotechnology company developing innovative treatments for cramps and spasticity associated with severe neurological diseases, such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). In October 2017, Flex Pharma initiated a Phase 2 study of CMT, referred to as the COMMIT study. The study will evaluate FLX-787, the Company’s co-activator of TRPA1 and TRPV1, in patients with CMT who suffer from muscle cramps. Approximately 120 subjects at 20 study centers across the United States are expected to take part. Participants will be in the study for approximately three months and will visit the study clinic three times. Enrollment is currently ongoing.
“Many of our patients with CMT neuropathy suffer from frequent and severe muscle cramping which can limit their activities of daily living and have a profound impact on their quality of life,” reported CMT clinical trial lead investigator, Dr. Nicholas Johnson, Assistant Professor of Neurology, Pediatrics and Pathology at the University of Utah. “We are hopeful FLX-787 will provide significant clinical advantages because of its safety profile and the lack of systemic exposure.”
Dr. William McVicar, Flex Pharma President and CEO, added “An important goal of the Hereditary Neuropathy Foundation (HNF) is to raise awareness of inherited neuropathies, such as CMT. Flex Pharma and the HNF both support research aimed at addressing the needs of patients, so we are excited to be partnering with the HNF in this effort to find a treatment for CMT patients suffering from painful cramps that impact their quality of life.”